Get started
Author

Jordan L. Plieskatt

Observed names: J. L. Plieskatt, J. Plieskatt, J.L. Plieskatt, JORDAN PLIESKATT, Jordan L Plieskatt, Jordan Plieskatt, L, Jordan, Plieskatt, J., Plieskatt, Jordan, Plieskatt, Jordan L, Plieskatt, Jordan L.
Observed institutions: Statens Serum Institut, Universidade Federal de Minas Gerais, National Institutes of Health, Program for Appropriate Technology in Health, The University of Queensland, Baylor College of Medicine, George Washington University, Cornell University, QIMR Berghofer Medical Research Institute, National Institute of Allergy and Infectious Diseases, Texas Children's Hospital, Sabin Vaccine Institute, New York State College of Veterinary Medicine, Fundação Oswaldo Cruz
ORCID: 0000-0002-2333-7234
Observed ORCID: 0000-0002-2333-7234
OpenAlex ID: A5083531297
Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals
2005 · Jeffrey Bethony, Alex Loukas, et al. · The FASEB Journal · 183
Infection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome
2013 · Jordan L. Plieskatt, Raksawan Deenonpoe, et al. · The FASEB Journal · 140
Ancylostoma caninum MTP-1, an Astacin-Like Metalloprotease Secreted by Infective Hookworm Larvae, Is Involved in Tissue Migration
2006 · Angela L. Williamson, Sara Lustigman, et al. · Infection and Immunity · 107
Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials
2005 · Gaddam Narsa Goud, Maria Elena Bottazzi, et al. · Vaccine · 98
An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection
2009 · Mark S. Pearson, Jeffrey M. Bethony, et al. · The FASEB Journal · 88
PDF
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area
2019 · W.A. Keitel, G.E. Potter, et al. · Vaccine · 62
Expression, Immunogenicity, Histopathology, and Potency of a Mosquito-Based Malaria Transmission-Blocking Recombinant Vaccine
2012 · D. K. Mathias, J. L. Plieskatt, et al. · Infection and Immunity · 56
Lessons along the Critical Path: Developing Vaccines against Human Helminths
2018 · David J. Diemert, Maria Elena Bottazzi, et al. · Trends in Parasitology · 51
Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini
2014 · Jordan L. Plieskatt, Gabriel Rinaldi, et al. · Journal of Hepatology · 42
Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates
2016 · Shwu-Maan Lee, Chia-Kuei Wu, et al. · Malaria Journal · 40
PDF
A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma
2015 · Jordan Plieskatt, Gabriel Rinaldi, et al. · BMC Cancer · 40
PDF
Expression at a 20L scale and purification of the extracellular domain of theSchistosoma mansoniTSP-2 recombinant protein
2013 · Elena Curti, Clifford Kwityn, et al. · Human Vaccines & Immunotherapeutics · 39
PDF
Circumventing qPCR inhibition to amplify miRNAs in plasma
2014 · Jordan L Plieskatt, Yanjun Feng, et al. · Biomarker Research · 37
PDF
Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
2021 · Susheel K. Singh, Jordan Plieskatt, et al. · npj Vaccines · 35
PDF
N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
2017 · Shwu-Maan Lee, Chia-Kuei Wu, et al. · Clinical and Vaccine Immunology · 35
PDF
Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma
2014 · Jordan L Plieskatt, Gabriel Rinaldi, et al. · Journal of Translational Medicine · 34
PDF
Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
2022 · Wei-Chiao Huang, Moustafa T. Mabrouk, et al. · Communications Biology · 33
PDF
A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system
2020 · Shwu-Maan Lee, John M. Hickey, et al. · Scientific Reports · 31
PDF
Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): A production process developed for a lead candidate recombinant hookworm vaccine antigen
2012 · Gaddam Narsa Goud, Vehid Deumic, et al. · Protein Expression and Purification · 31
Reduction of Worm Fecundity and Canine Host Blood Loss Mediates Protection against Hookworm Infection Elicited by Vaccination with Recombinant Ac- 16
2007 · Ricardo T. Fujiwara, Bin Zhan, et al. · Clinical and Vaccine Immunology · 31
A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
2021 · Susheel K. Singh, Jordan Plieskatt, et al. · Frontiers in Immunology · 29
PDF
Potency testing for the experimentalNa-GST-1 hookworm vaccine
2010 · Amar R Jariwala, Luciana M Oliveira, et al. · Expert Review of Vaccines · 29
The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable
2019 · Susheel K. Singh, Jordan Plieskatt, et al. · Journal of Biological Chemistry · 27
PDF
ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum
2019 · Kazutoyo Miura, Bingbing Deng, et al. · Vaccine · 23
A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults
2024 · Alfred B. Tiono, Jordan L. Plieskatt, et al. · Journal of Clinical Investigation · 22
PDF
Works count: 77
Citation count: 1,632
H-index: 23
I10-index: 41
Year
Topic
Type